Calculated NOK return from USD · USD Class R Dist (NOK Calculated)
Last NAV 71,87 USD · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+7,0 %
1y
+21,2 %
3y, annualised
+13,5 %
5y, annualised
+17,6 %
10y, annualised
Fund size
2,9 mrd. USD
Total fund AUM
Ongoing charge
1,57 %
Annual · class R USD
Performance fee
10%
of the excess return
Annual cost on platforms
1,40 %
Class R USD · 2 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
Oct 2013
ISIN IE00B3XLHR60
BenchmarkNasdaq Biotechnology · Net
About the fund
The fund
Polar Capital Biotechnology Fund was launched in 2013, when David Pinniger joined Polar Capital to start it. The management company, Polar Capital, is a specialist active manager founded in 2001 and headquartered in London. Its parent, Polar Capital Holdings, is listed on AIM in London and has dispersed ownership. Investment management is split into relatively autonomous sector and thematic teams.
Investment philosophy
The fund is focused on biotechnology, has a global mandate and is not restricted to particular company sizes. The benchmark is the NASDAQ Biotechnology Net Total Return Index. It is the fund in Polar Capital's healthcare team that is specialised in biotechnology, while the team's other funds have a broader healthcare mandate.
The managers
David Pinniger and Gareth Powell have managed the fund since its launch in 2013, and both are based in London. Powell set up Polar Capital's healthcare team in 2007 and leads it. He previously managed the Framlington Biotech Fund from 2004. Pinniger joined Polar Capital in August 2013 from SV Life Sciences, where he managed the International Biotechnology Trust. He has also been an analyst at the venture firm Abingworth and at Morgan Stanley. Both were educated at Oxford and are CFA charterholders. Deane Donnigan, a pharmacist and former manager of healthcare and biotechnology funds at Framlington, and James Douglas, who holds a PhD in medicinal chemistry, are also listed as managers. The team also manages funds such as Polar Capital Healthcare Opportunities Fund and Polar Capital Global Healthcare Select Fund.
The portfolio
The portfolio has a high active share against the benchmark. Its volatility has been in line with comparable funds, so the specialisation has not brought higher volatility. Biotechnology and pharmaceuticals are the lasting sectors, and the US is the largest country. Companies such as Argenx, Ascendis Pharma, Amgen, Alnylam Pharmaceuticals, Rhythm Pharmaceuticals, Madrigal Pharmaceuticals and Xenon Pharmaceuticals have recurred as steady holdings.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.